Atrial Electrogram Analysis for ROS-Associated Tissue Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective detection and ablation techniques for reactive oxygen species (ROS)-associated cardiac tissue in atrial fibrillation (AF), which hinders the success of AF ablation procedures, especially in patients with structural heart disease.
Innovation Solution
The method involves analyzing atrial electrograms (EGMs) to identify ROS-associated cardiac tissue using correlations with EGM characteristics before and after ROS blockade, and employing therapeutic DNA, such as dominant negative TGF-β R2 cDNA or NOX2 shRNA, to reduce ROS production, guiding targeted ablation therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional ablation methods are used without ROS detection, then the ablation procedure can be performed, but the precision and success rate of AF ablation is reduced
Solution Approach 1:
The patent uses EGMs as an intermediary signal to indirectly detect ROS-associated tissue characteristics. By analyzing EGM features (fractionated signals, frequency content, amplitude variations) that correlate with ROS presence, the method enables precision detection without requiring direct ROS measurement tools. This intermediary approach resolves the contradiction by providing sufficient detection precision through electrical signal analysis.
Solution Approach 2:
The patent replaces mechanical/biophysical ROS detection methods with electrical field-based EGM analysis. Instead of using physical probes to measure ROS directly, the invention utilizes the electrical activity already present in cardiac tissue (EGMs) to infer ROS-associated tissue characteristics, thereby achieving precise detection through a non-invasive electrical measurement approach.
2Manufacturing precision
If EGM analysis is performed to identify ROS-associated tissue, then the precision of ablation targeting is improved, but the complexity of the procedure increases
Solution Approach 1:
The patent leverages the universality of EGM recording technology, which is already a standard tool in cardiac electrophysiology procedures. By analyzing existing EGM data with advanced signal processing algorithms, the method achieves precise ROS-associated tissue identification without requiring separate dedicated detection devices, thus minimizing procedural complexity while maintaining high targeting precision.
Solution Approach 2:
The patent creates a virtual map of ROS-associated tissue by analyzing and processing EGM signals. Instead of physically marking or directly visualizing ROS tissue, the system generates an electrical signal-based representation (copy) of the tissue characteristics, which guides ablation targeting. This virtual mapping approach simplifies the overall system complexity compared to direct physical detection methods.
3Object-generated harmful factors
If therapeutic DNA is used to reduce ROS production, then ROS-associated tissue activity is reduced, but the treatment protocol becomes more complex
Solution Approach 1:
The patent extracts or suppresses the harmful ROS production pathway by introducing therapeutic DNA (such as siRNA or antisense oligonucleotides) that specifically targets and inhibits ROS-generating enzymes or pathways in cardiac tissue. This extraction of the harmful function (ROS production) directly addresses the contradiction by reducing harmful factors through a targeted molecular approach.
Data Source
AI summary
The invention relates generally to methods of detecting reactive oxygen species (ROS) in cardiac tissue and treatment modalities for ablating ROS-associated tissue in cardiac disease. The methods rely upon targeting ROS-associated cardiac tissue for ablation and/or gene therapy in a subject using analytical tools based upon a plurality of recorded atrial EGMs for a tissue to assess ROS content and underlying AF organization as a function of ROS blockade conditions.